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Abstract
Background/Objective: Corticobasal syndrome (CBS) is a rare neurodegenerative disorder characterized by a progressive
and asymmetric manifestation of cortical and basal-ganglia symptoms of different origin. The spatio-temporal dynamics of
cerebral atrophy in CBS is barely known. This study aimed to longitudinally quantify the individual dynamics of brain
volume changes in patients with CBS as compared to healthy controls.
Methods: We used deformation-field-based morphometry (DFM) to study volumetric changes of each individual brain in
short intervals of a few months. DFM enabled the quantitative analysis of local volume changes without predefining regions
of interest in MR images of 6 patients with CBS and 11 matched healthy controls. A total of 64 whole brain 3D-MR-scans
were acquired two to eight times over periods of 14 to 26 months. Based on repeated registrations of MR observations to
the initial scan, maps of local volume ratio changes were computed.
Results: Compared to controls patients showed significant and increasing volume loss over time in premotor and primary-
motor-cortices, somatosensory area 3a, superior parietal areas BA 5/7, and corticospinal tract. Furthermore, significant and
asymmetric atrophy was identified in the caudate nucleus head, putamen, pallidum, motor-thalamus and substantia nigra.
Temporal lobe was affected in those patients who presented progressive cognitive impairment.
Conclusions: The analysis revealed localized, pathological changes in brains of patients with CBS, which differed
significantly from those occurring during aging in healthy controls. As compared to age- and sex-matched controls, brains
of CBS patients showed a common degenerating neural network comprising the motor circuit with basal ganglia and motor
thalamic nuclei as well as the premotor and primary-motor-cortex.
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Introduction
Although structural changes have been reported in patients with
corticobasal syndrome (CBS) using neuroimaging [1,2,3,4], the
individual dynamics of progression of clinical symptoms in CBS
and their relationship to the topography of structural changes that
segregate the neurodegenerative effects are not well understood. In
particular at the beginning of the disease local structural changes
are indiscernible from those observed during normal aging due to
considerable intersubject variability. The currently available tools
for the analysis of MR images mainly lack the necessary sensitivity
for detecting small changes that occur over a relatively short
period of time, such as few months. However, in CBS and other
neurodegenerative diseases such tools are desperately needed for
an early clinical diagnosis and for the identification of treatment
strategies that may modify the disease progression [5].
CBS is a rapidly progressing disease, which comprises different
entities including corticobasal degeneration (CBS-CBD), Alzhei-
mer disease (CBS-AD), progressive supranuclear palsy (CBS-PSP),
frontotemporal lobar degeneration (FTLD), multisystem tauopa-
thy, and parkinsonism linked to chromosome 17, wherefore
pathological diagnosis is required as gold standard [6,7,8]. The
nomenclature and included subtypes, however, are still a matter of
discussion [9].
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In 24–55% of all patients presenting with symptoms of CBS the
underlying pathology is CBS-CBD [7,10]. CBS-CBD commences
between the age of 60–80 with typical signs of a progressive,
asymmetric, akinetic-rigid syndrome including the clinical hall-
marks of an ideomotor limb apraxia, alien limb syndrome and
cortical sensory loss that respond poorly to levodopa therapy [11].
In addition, CBS-CBD can lead to frontotemporal dementia and
non-fluent aphasia [10]. Due to this clinical heterogeneity, an
overlap with other neurodegenerative diseases is common and
may lead to clinical misdiagnosis [9]. In patients with clinical
diagnosis of CBS-CBD, only 50% revealed pathologically proven
CBD, and PSP was mainly detected in false positive cases [7,10].
Furthermore, unusual types of Alzheimer’s disease with prominent
motor features or FTLD may have a similar clinical presentation
[7,8,9,10].
Themajor histopathological feature of CBS-CBD is a widespread
accumulation of abnormal phosphorylated tau protein in both glial
cells and neurons, astrocytic plaques, and coiled bodies with gliosis of
the substantia nigra [12]. Focal cortical neuronal loss and underlying
white matter degeneration is primarily present in sensory andmotor
areas of the parietal and frontal cortex with relative sparing of
temporalaswellasoccipital regions[11].However, the localizationof
these findings overlaps with other tauopathies that may explain
clinical similarity, leading to anongoing discussion if these diseases in
fact reflect separate entities [8,9].
During the last years different functional and morphometric in-
vivo studies (primarily cross-sectional) focused on the subtype
differentiation of CBS [3,4,13]. Recently, Whitwell and colleagues
published cross-sectional imaging findings of autopsy-proven CBS
patients [4]. According to the pathological diagnosis, an increased
Table 1. Demographics and clinical findings of CBS patients.
Case 1 Case 2 Case 3 Case 4 Case 5 Case 6
Gender f m m f f m
Age, y 72 69 76 68 62 65
Education, years ,12 ,12 ,12 .12 .12 ,12
Disease duration, years 1 2 2 2 3 4
Clinical asymmetry ri . le le . ri le . ri le . ri ri . le ri . le
Diagnostic MRI (T initial) normal normal atrophic atrophic normal atrophic
MRI acquisition (Tesla) 1.5 3.0 3.0 3.0 3.0 1.5
Follow-up, months 26 25 24 14 16 19
Clinical signs (T initial/final)
Rigidity +/+ +/+ +/+ +/+ +/+ +/+
Bradykinesia +/+ +/+ +/+ +/+ +/+ +/+
Ideomotor apraxia +/+ +/+ +/+ +/+ +/+ +/+
Alien limb syndrome 2/+ 2/+ 2/+ 2/2 +/+ +/+
Dystonia 2/+ 2/2 +/+ +/+ 2/+ +/+
Astereognosia 2/+ 2/2 2/+ 2/+ 2/2 2/+
Myoclonus 2/2 +/+ 2/2 2/2 +/+ +/+
Mirror movements 2/+ 2/+ +/+ 2/2 2/2 2/2
Speech apraxia 2/+ 2/+ 2/2 2/+ 2/2 2/2
Supranuclear palsy 2/2 2/+ 2/+ 2/+ 2/2 2/2
Babinski sign 2/+ 2/2 2/2 +/+ 2/2 2/2
Motor testing
UPDRS-III (T initial, Off/On) 18/18 22/21 35/33 45/44 21/20 25/25
UPDRS-III (T final, On) 33 46 58 64 45 32
FT values (T initial, ri/le) 3/42 49/38 32/12 57/0 18/44 1/26
FT values (T final, ri/le) 0/19 0/0 12/0 35/0 8/25 0/7
Florida Apraxia Score
T initial (ri/le) 56/4 2/30 0/14 5/56 37/18 52/33
T final (ri/le) 60/49 38/54 8/28 13/56 42/25 54/51
Neuropsychological testing
MMSE (T initial) 29/30 27/30 22/25 29/30 30/30 25/30
MMSE (T final) 29/30 19/30 21/25 29/30 27/30 26/30
MDRS (T initial) n.d. 126/144 94/103 142/144 144/144 n.d.
MDRS (T final) 133/144 96/144 90/103 143/144 131/144 107/144
Abbreviations: MMSE = Mini Mental State Examination, MDRS = Mattis Dementia Rating Scale, MRI = Magnetic resonance imaging, n.d. = not done, UPDRS-III =
Unified Parkinson’s Disease Rating Scale part III, FT = Finger tapping, le = left, ri = right, f = female, m = male, T initial = initial examination, T final = final
examination, 2 = absent, + = present.
doi:10.1371/journal.pone.0041873.t001
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Table 2. Local volume ratio (LVR) changes (Median 6 SEM) as % for different cortical and subcortical regions of 11 healthy
controls and 6 CBS patients at final follow-up examination (T final) as compared to the initial examination (T initial).
Controls CBS P value Controls CBS P value
contralateral contralateral ipsilateral ipsilateral
Global Hemisphere 20.2260.13 21.2560.38 0.18 20.3660.12 21.0960.37 0.22
Frontal cortex
area 4 c 0.0360.20 23.0761.92 0.0002* 20.3660.19 23.3661.04 0.0002*
area 6 c 20.2560.22 23.6961.94 0.0002* 20.1260.20 23.5361.29 0.0002*
superior frontal gyrus m 20.2160.22 20.8060.58 0.40 20.4160.18 21.4060.78 0.30
medial frontal gyrus m 20.1260.27 20.4960.51 0.40 20.4760.15 21.1860.71 0.03
inferior frontal gyrus m 20.1760.24 0.5960.36 0.35 20.3460.18 20.8260.63 0.52
orbitofrontal cortex (10,11,47) m 20.1661.32 1.8561.79 0.06 20.5260.79 20.5560.91 0.65
gyrus rectus m 20.6260.30 1.2260.77 0.05 20.1360.32 0.9960.65 0.08
Broca’s area (44/45) c 20.2860.27 20.0560.41 0.73 20.3060.19 21.2460.66 0.22
Parietal cortex
area 3a c 20.4660.28 23.2161.10 0.01* 20.5460.27 22.7960.80 0.01*
area 3b c 20.0360.18 21.9660.98 0.09 0.0660.18 21.4660.74 0.22
area 1 c 0.2760.31 21.7760.74 0.05 0.1260.25 21.4360.61 0.08
area 2 c 0.0260.24 21.7860.81 0.03 20.0260.24 20.6160.78 0.40
superior parietal lobule (5,7) c 20.1060.20 22.6260.43 0.001* 20.1860.19 21.4760.66 0.007*
Precuneus c 20.0660.28 20.8160.37 0.15 0.2160.31 20.7560.70 0.18
inferior parietal lobule c 0.2660.20 20.9360.67 0.52 20.1960.18 20.1560.56 0.96
Occipital cortex
primary visual cortex c 20.0460.16 0.2160.51 0.59 20.2360.12 0.2360.40 0.22
secondary visual cortex c 20.2960.17 20.2660.54 0.81 20.1760.14 20.5160.53 0.52
lingual gyrus m 20.1960.19 0.2760.48 0.59 20.0860.13 0.1460.48 0.66
Cuneus m 20.2360.18 0.3360.47 0.59 0.3160.20 0.0560.45 0.73
Temporal cortex
superior temporal gyrus m 20.3660.14 0.4660.95 0.40 20.3860.16 0.4260.46 0.18
medial temporal gyrus m 20.4560.19 0.1160.90 0.66 20.4760.23 20.4060.85 0.73
inferior temporal gyrus m 20.1360.18 20.1261.17 1.00 20.3060.18 20.2760.90 0.88
Amygdale c 20.1860.25 0.4660.95 0.59 20.4560.23 0.4260.46 0.30
entorhinal cortex c 20.1460.31 21.2260.82 0.18 0.1460.32 21.2760.89 0.40
fusiform gyrus m 20.2160.15 20.2460.76 1.00 20.5160.18 20.7960.66 0.22
parahippocampal gyrus m 20.1560.34 0.0461.05 0.88 0.2060.35 1.0961.00 0.26
TE3 (Wernicke) c 0.1460.26 0.8260.94 0.59 20.7360.39 0.2360.80 0.30
Basal ganglia
caudate nucleus m 20.6160.25 20.3160.45 0.96 20.4360.19 2.0460.85 0.05
head of caudate nucleus m 20.4760.21 22.7660.41 0.0006* 20.0960.23 21.6760.81 0.30
Putamen m 20.7360.19 23.8460.76 0.0001* 20.5660.23 22.6960.93 0.001*
Pallidum m 20.8660.21 23.8360.91 0.0006* 20.4060.26 23.7661.14 0.01*
Thalamus
central medial nuc. c 21.8460.30 22.2460.42 0.46 20.9560.41 22.5060.53 0.03
dorsomedial nuc. c 21.1660.59 22.7660.59 0.35 20.7260.38 22.3261.46 0.18
lateral posteriordorsal nuc. c 21.0060.33 0.8560.42 0.18 21.0460.28 0.7660.25 0.15
anterior nuclei c 20.6960.46 0.1160.84 0.29 –0.7160.35 0.2360.58 0.39
ventral anterior nuc. c 20.7960.22 23.0660.68 0.0003* 20.5260.27 24.4260.88 0.003*
ventral lateral nucl. c 20.4760.20 23.6760.70 0.0001* 20.6560.26 22.2860.91 0.05
ventral posterior nuc. c 20.9760.29 21.5560.87 0.46 20.3360.19 21.6960.80 0.46
pulvinar c 21.5460.30 0.1761.55 0.15 21.0460.18 0.3960.90 0.05
Midbrain
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focal cortical atrophy in the premotor und supplementary motor
area was due to CBS-CBD and CBS-PSP pathology, whereas
FTLD revealed a stronger frontotemporal and CBS-AD a more
prominent temporo-parietal pattern of atrophy.
We here applied magnetic resonance imaging (MRI) and
deformation field morphometry (DFM) in six clinically diagnosed
CBS patients and eleven age- and sex-matched healthy controls
from an ongoing follow-up study employing a longitudinal design.
Table 2. Cont.
Controls CBS P value Controls CBS P value
contralateral contralateral ipsilateral ipsilateral
nucleus ruber c 20.2860.27 21.2560.67 0.03 20.9060.30 22.3460.96 0.15
substantia nigra m 20.4460.25 22.5861.15 0.001* 20.1360.33 24.0961.06 0.007*
Cerebellum
anterior lobe m 20.0260.23 20.6460.68 0.66 20.2560.25 20.8260.72 0.52
posterior lobe m 0.0660.20 20.2460.46 0.81 20.1260.16 20.5060.46 0.88
Ventricles m 3.3961.43 18.7564.84 0.007* 1.6760.66 17.4964.08 0.002*
Corticospinal tract f 20.5760.19 24.3061.21 0.0002* 20.3460.17 23.9260.85 0.0003*
P values are given for a two-sided Mann-Whitney-U-test. *indicates significant P values (corrected for multiple comparisons by controlling the false discovery rate at
0.05). F indicates myeloarchitectonically defined maps of fibers, M indicates macroanatomically and C cytoarchitectonically defined areas.
doi:10.1371/journal.pone.0041873.t002
Figure 1. Statistical maps (A: coronal and B: axial sections) of voxel-wise volume differences (upper trace) in comparison to
probabilistic maps of cytoarchitectonically defined areas (lower trace) between 6 CBS patients and 11 age- and sex-matched
controls (P,0.01). The colored bar represents the T score of significant voxels (red to yellow indicate volume decline, blue indicate volume
increase). Abbreviations: IPL = Inferior Parietal Lobule, CN = Caudate Nucleus, CST = Corticospinal Tract, SPL = Superior Parietal Lobule, VP =
Ventral Posterior Nucleus of the thalamus, VA = Ventral Anterior Nucleus of the thalamus, C = Contralateral to the clinically most affected side, I =
Ipsilateral to the clinically most affected side.
doi:10.1371/journal.pone.0041873.g001
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Figure 2. Longitudinal local volume ratios (percent, y-axis) during follow-up examination (months, x-axis) of different cortical
regions, the corticospinal tract and lateral ventricles that revealed significant group differences between CBS patients (coloured
lines) and controls (grey lines). Note that the y-axis of the lowermost graph is differently scaled.
doi:10.1371/journal.pone.0041873.g002
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Figure 3. Longitudinal local volume ratios (percent, y-axis) during follow-up examination (months, x-axis) of different subcortical
regions that revealed significant group differences between CBS patients (coloured lines) and controls (grey lines).
doi:10.1371/journal.pone.0041873.g003
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Figure 4. Longitudinal local volume ratios (percent, y-axis) during follow-up examination (months, x-axis) of different cortical and
subcortical regions that revealed no significant group differences between CBS patients (coloured lines) and controls (grey lines).
Note that at individual level in cases 3 and 6 a mild affection of the inferior temporal gyrus is evident.
doi:10.1371/journal.pone.0041873.g004
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DFM is capable of detecting even subtle regional volume changes
in the entire brain in small samples. The topography of significant
volume changes was identified using probabilistic maps of
cytoarchitectonic areas [14,15,16].
Methods
A sample of six patients with the clinical diagnosis of CBS
attending the Movement Disorder Centre of the University
Hospital Du¨sseldorf was prospectively recruited. At the time point
of study inclusion (T initial) all patients underwent detailed
neurological examination (including testing of the autonomic
nervous system and formal psychometry using Florida Apraxia
Screening Test (FAST) [17], Mattis Dementia Rating Scale
(MDRS) [18], Mini Mental State Examination (MMSE) [19]),
routine laboratory tests, and volumetric as well as diagnostic
magnetic resonance brain imaging to exclude symptomatic
parkinsonism during hospitalization over a time period of 5–
8 days. Additionally, the Unified Parkinson Disease Rating Scale
part III (UPDRS-III) was determined 12 hours after discontinu-
ation of antiparkinsonian medication and after oral administration
of 250 mg L-Dopa [20]. Furthermore, one minute of finger
tapping (FT) was performed with the left and right forefinger;
subjects were required to alternatingly press specific counting
devices which were fixed on a board as rapidly as possible. In
addition, all patients underwent clinical and MRI follow-up
examinations performed on the same day during the course of
20.765 months (4–8 serial MRIs). In most cases, intervals
between consecutive scans were about three to four months. Final
diagnosis of CBS was made in a consensus panel arrangement by
two movement disorder specialists (A.S., M.S.), taking into
consideration data of carefully assessed longitudinal neurologic
follow-up examinations, possible response to dopaminergic treat-
ment, diagnostic MRI and published clinical criteria [6,21,22]. No
subjects were excluded from the study, but two follow-up scans
were discarded from further analysis due to movement artefacts.
The control group consisted of eleven age- and sex-matched,
right-handed healthy volunteers with no previous history of
neurological or medical disorder, who underwent
21.462.7 months of follow-up with 2–4 serial MRIs obtained
(Table S1).
Ethics
Patients examined in this study were recruited from a large
longitudinal studyonpatientswithmovementdisorders, approvedby
the local ethics committee (study-no. 2849, ‘‘Ethikkommission der
Medizinischen Fakulta¨t der Heinrich-Heine-Universita¨t Du¨ssel-
dorf’’, http://medfak.uni-duesseldorf.de/dekanat/kommissionen/
ethikkommission/, Ethikkommission@med.uni-duesseldorf.de).
The procedure and the reason for this examination in particular
were explained to all patients and carers as well as healthy controls in
full detail. At study inclusion all patients had adequate capacity/
ability topersonally givewritten informedconsent as approvedby the
detailed neurological and neuropsychological testing. The study is in
accordance with the Declaration of Helsinki.
MRI
Brains of the patients and the healthy controls were scanned in a
1.5 Tesla (Magnetom Vision, Siemens Medical Solutions; Erlan-
gen, Germany) or 3 Tesla (Magnetom Trio Tim System, Siemens
Medical Solutions; Erlangen, Germany) MR-tomograph with a
standard CP head coil. Pulse sequences were as follows: sagittal 3D
gradient echo sequence (repetition time (TR) 9.7 ms, echo time
(TE) 4 ms, 1 mm slice thickness for 1.5 Tesla and TR 2300 ms,
TE 2.98 ms, 1 mm slice thickness for 3 Tesla, with one signal
acquired), field of view (FOV) 256-mm and 2566256 matrix. All
follow-up scans of a single patient or control were acquired by
using the same scanner as for the initial scan (Table 1, Table S1).
Deformation Field Morphometry (DFM)
A detailed description of the applied morphometric technique
has been published [16]. Hence, we only provide a brief outline
here. Serial MR images of each subject were examined for
intraindividual differences between each follow-up and the initial
MR image (Ti). Therefore, the follow-up images were registered to
the initial image using a non-linear registration. As a result of
registration, deformation fields were calculated for each subject
and each follow-up imaging. The deformation fields were
transformed to ‘‘local volume ratio’’ (LVR) maps [16]. The
LVR data indicate voxel-wise volume differences of the brain
between the initial and corresponding follow-up MR observations.
Therefore, a sequence of each subject’s LVR maps encodes
structural changes in each voxel of the brain.
Analysis of Anatomical Brain Regions
LVR maps were analysed in two different ways [16]: (a) Voxel-
wise analyses; maps showing individual changes of brain structure
in the native space of each subject were generated, as well as
statistical maps showing differences on the group level. The latter
analysis required all subjects’ LVR-maps of the last examination to
be transformed into the standard space of the MNI single-subject
template [23]. Differences between the transformed maps were
examined by SPM 8 (http://www.fil.ion.ucl.ac.uk/spm). Voxel-
wise analyses enable to visualize small regional effects. On the
other hand, they are also prone to uncertainties due to image
registration, which may impact voxel-wise statistical analysis. (b)
Volume changes of anatomical regions; such changes were
calculated as the weighted sum of the voxel-wise LVR-values
(see below) in regions of interest. Hence the impact of registration
errors of single voxels is reduced as compared to a), the robustness
of the volume measures is higher. In addition, reducing the volume
change data of millions of voxels to a much lower number of
regional volume data permits a better visualization. For example,
representations of individual time-dependent volume changes as
charts provide important information about the individual course
of the disease as well as inter-individual variability in an intuitive
manner, whereas similar representations by statistical parametric
maps are hardly possible.
Probabilistic maps of cytoarchitectonically defined cortical areas
and subcortical nuclei, as well as myeloarchitectonically delineated
fiber tracts (http://www.fz-juelich.de/inm/inm-1) were used for
measurements of localized changes in circumscribed anatomical
entities. These structures have been delineated in histological sections
of ten post-mortem brains [14,24,25,26]. The probabilistic maps
were registered to the T1-weighted single-subject template of the
Montreal Neurological Institute (MNI) [23]. In the present study,
cytoarchitectonic maps of somatosensory and motor cortex areas as
well as the superior parietal lobule were particularly relevant
[27,28,29,30]. In addition to the presently available probabilistic
cyto- and myeloarchitectonic maps, which do not cover the entire
cortex and subcortical nuclei, maps of macroanatomically defined
structures of the MNI template (http://www.loni.ucla.edu/ICBM/
Downloads/Downloads_ICBMtemplate.shtml) were used whenever
necessary. All anatomical maps (macrostructural as well as myelo-
and cytoarchitectonic) were warped onto each brain volume [15,16].
For each case, relative volume changes of cyto- and myeloarchi-
tectonically defined regions of interest were calculated as the sum of
voxel-wise LVR-values weighted by the voxel-values of probabilistic
Dynamics of Brain Atrophy in CBS
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cyto- or myeloarchitectonical maps:
DvRegion tkð Þ~
P
~x[VRegion
LVR ~x,tkð Þ:pRegion ~xð Þ
P
~x[VRegion
p
Region
~xð Þ
DvRegionI(tk) = relative volume change of the anatomical region under
consideration at time point tk relative to the initial measurement, tk =
time point of a follow-up scan (k$1),VRegion = set of voxels belonging
to the region (at the initial measurement),LVR ~x,tkð Þ= local volume
ratio in voxel ~x at the follow-up measurement at time point tk,
pRegion ~xð Þ = probabilistic value of the region in voxel~x.
Statistical Evaluation
For statistical comparison of the demographic and clinical
parameters between CBS patients and control subjects the two-
sided t-test was used for normally distributed and the two-sided
Mann-Whitney-U-test for non-normally distributed data. Normal-
ity of data distribution was assessed using the Kolmogorov-
Smirnov test. Differences of p,0.05 were considered significant.
Further, we analysed the dynamics of intraindividual volume
reduction in myeloarchitectonically defined fiber tracts, cytoar-
chitectonic areas as well as macroanatomically defined cortical and
subcortical areas in CBS patients and controls. Between-group
differences of local volume changes at the last follow-up
examination were assessed using the two-sided Mann-Whitney-
U-test to determine those brain areas, where volume loss was
significantly greater in CBS patients than in healthy controls. All
controls were right-handed wherefore we defined left-hemispheric
data as ‘‘contralateral’’ and right-hemispheric data as ‘‘ipsilateral’’.
This explorative analysis was applied to all brain regions. Testing
multiple brain regions in parallel increases the risk of false positive
findings. However, the commonly used Bonferroni’s method to
control the family wise error will become conservative, in
particular when correlations between the tests are present. Such
correlations are to be expected, because volume changes of the
brain which are caused either by normal aging or by neurode-
generative disease, will in general affect systems of anatomical
entities in the brain. Moreover, Bonferroni’s method corrects for
the occurrence of any false positive result. Therefore, we chose to
control the ‘‘False discovery rate’’ at 0.05 in order to correct for
multiple comparisons [31,32]. In addition, the complementary
voxel-wise analysis of group differences was calculated in SPM 8.
The gender of the participants and the MR scanner which was
used for the image acquisition are two further factors which could
intermingle with differences between both patients and controls.
The sample size, however, was too low to consider these factors in
a multi-way statistical analysis and both groups were balanced
against the factor gender (number of males/females: controls 5/6,
patients 3/3). Therefore, a gender-related confounding effect was
not expected. The effect of the different MR scanner type was
analyzed by calculating a t-test of differences between the 1.5-
Tesla- and 3.0-Tesla scans within the control group, which did not
reach significance. Therefore, both factors were not further
considered in the following analyses. Moreover, it should be
stressed, that each participant’s sequence of MR scans was
acquired in the same scanner (i.e. there was no mixing of scans
from different scanners within the same participant).
Descriptive statistics and basic comparisons were analyzed using
the MedCalC software package (MedCalc 11.1, Belgium).
Clinical Parameters
None of the patients had other neurologic diseases or family
history for dementia and parkinsonism. Motor symptoms showed
no positive response to levodopa during levodopa-test or
continuing dopaminergic therapy.
Case 1
A 72-year-old woman presented with a 1 year history of
progressive rigidity, bradykinesia and ideomotor limb apraxia
(IMA) of her right arm at the time of initial volumetric MRI.
Neuropsychological evaluation and diagnostic MRI scans were
normal. During the 26-months follow-up period (examinations
after 16, 20, 23, 26 months) the hypokinetic-rigid syndrome
(UPDRS-III 18 R 33), and ideomotor apraxia worsened
significantly and additionally affected the left upper extremity.
Furthermore, a right-sided cortical sensory loss in terms of a tactile
agnosia, speech apraxia, Babinski sign and alien limb syndrome
appeared. There were no clinical features of clonus or muscle
atrophy. After 26 months of follow-up, she revealed no cognitive
impairments besides mild visuoconstruction and attention deficits
(MDRS 133/144).
Case 2
A 69-year-old man complained that over the last 2 years his left
upper extremity became clumsy and useless. At initial follow-up
examination he revealed a moderate left-dominant hypokinetic-
rigid syndrome (UPDRS-III 21) as well as myoclonus and
ideomotor apraxia of the left hand. Diagnostic brain MRI scans
were normal. Neuropsychological testing detected mild deficits in
the subitems attention, initiation-perseveration as well as con-
struction of the MDRS (total score 126/144); memory subscales
were normal. During the 25-months follow-up period (examina-
tions after 3, 6, 10, 13, 18, 22, 26 months) the hypokinetic-rigid
syndrome dramatically worsened (UPDRS-III 21R 46) and a left
upper alien limb syndrome appeared. Furthermore, ideomotor
apraxia became bilateral and a speech apraxia was evident. He
developed a vertical supranuclear palsy and postural instability.
His abilities on formal psychometric testing deteriorated and
MDRS declined to 96, showing worsening of attention, initiation-
perseveration and construction as well as onset of memory deficits.
Case 3
A 76-year-old man progressively developed a stiffness and
uselessness of his left arm and leg over the course of 2 two years.
Figure 5. Topography of brain volume changes as detected by DFM analysis in comparison to probabilistic maps of
cytoarchitectonically defined areas that were superimposed on each individual MRI-Scan in (A–C) three CBS patients (case 1, 2
and 6) and (D) a healthy control during long-term follow-up examination. The color coding of the voxels indicate the time interval since the
initial scan, when their volume had declined by 5% relative to the initial time point. Thus these images show the temporal spreading of the atrophy in
each subject’s brain (e.g. red or yellow mean, that after 10 or 20 months, respectively, the voxel volume had shrunk by 5%). Note that in (A) patient 1
and (B) patient 2 showed a more prominent volume decline within area 6 and basal ganglia nuclei, whereas (C) patient 6 revealed lesser volume
changes with stronger involvement of temporal regions. The control brain (D) showed only minimal brain volume alterations. Abbreviations: CN =
Caudate Nucleus, CST = Corticospinal Tract, IPL = Inferior Parietal Lobule, SPL = Superior Parietal Lobule, VA = Ventral Anterior Nucleus of the
thalamus, VL = Ventral Lateral Nucleus of the thalamus, VP = Ventral Posterior Nucleus of the thalamus, L = Left, R = Right.
doi:10.1371/journal.pone.0041873.g005
Dynamics of Brain Atrophy in CBS
PLoS ONE | www.plosone.org 10 July 2012 | Volume 7 | Issue 7 | e41873
At initial examination he presented with a left-dominant moderate
hypokinetic-rigid syndrome (UPDRS-III 33). Furthermore, he was
affected by a solely left-sided ideomotor apraxia and dystonia.
Diagnostic MRI scans demonstrated cortical atrophy pronounced
in fronto-parietal regions accompanied by a ventricular widening.
The neuropsychological examination was limited since the patient
was nearly blind due to a senile macular degeneration. Therefore,
only verbal testing was possible and MDRS was reduced to a
maximum of 103 and MMSE to a maximum of 25 points. He
initially revealed minimal deficits in the domains initiation-
perseveration and attention. Memory functions, orientation and
conceptualization were normal. During the 24-months follow-up
(examinations after 11, 14, 20, 24 months), he developed a severe
bilateral but left-dominant akinetic-rigid syndrome (UPDRS-III up
to 58) and ideomotor apraxia of all limbs. He became chairbound
due to the apractic gait dysfunction. Furthermore, he developed an
alien limb syndrome and astereognosia of the left arm as well as a
supranuclear palsy. Psychometry revealed worsening of initiation-
perseveration and onset of mild memory deficits.
Case 4
A 68-year-old woman developed a severe akinetic-rigid
syndrome (UPDRS-III 44) with dystonic and painful contraction
of the left upper and lower extremity over the last 2 years. The left
leg became apractic with consecutive gait difficulties. Babinski sign
was positive, but there were no clinical findings of weakness,
hyperreflexia or fasciculations. Diagnostic MRI scans showed mild
to moderate cortical atrophy but detailed neuropsychological
testing was normal. After a 14-months follow-up period (exami-
nations after 7, 14 months) she was chairbound due to a gait
apraxia. The hypokinetic-rigid syndrome worsened and manifest-
ed bilaterally (UPDRS-III 44 R 64). Furthermore, a painful left-
dominant dystonia affected all limbs, wherefore initiation of
botulinum toxin injection was necessary. Moreover, a speech
apraxia and astereognosia developed. She still performed normal
on psychometric testing. Two months after the last follow-up
examination the patient died of a subacute ileus.
Case 5
A 62-year-old woman presented with a progressive stiffness,
slowness and difficulty using the right arm. At initial examination,
she had moderate hypokinetic-rigid syndrome (UPDRS-III 20),
ideomotor apraxia, alien limb phenomenon and myoclonus of the
right upper limb. Diagnostic MRI scans and detailed neuropsy-
chological testing were normal. During a 16-months follow-up
period (examinations after 4, 7, 10, 12, 16 months) the hypoki-
netic-rigid syndrome rapidly worsened and became bilateral
(UPDRS-III up to 45). The ideomotor apraxia as well as the
alien limb syndrome further increased and she developed a painful
dystonia of the right hand. At final visit, formal psychometry
revealed severe constructional apraxia as well as slight initiation-
perseveration impairment; memory functions were normal.
Case 6
A 65-year-old man suffered of a 4 year history of progressive
right-dominant upper ideomotor apraxia, dystonia, bradykinesia
and rigidity as well as right-sided alien limb syndrome. At the time
of first scanning neuropsychological examination revealed reduced
verbal fluency due to dysphasia, a moderate dyscalculia and slight
deficits of additional cognitive functions. Diagnostic brain MRI
demonstrated mild left-sided parietal-frontal atrophy. During the
19-months follow-up significant worsening of right-dominant
ideomotor apraxia and hypokinetic-rigid syndrome (UPDRS-III
25 R 32) was evident and a right-sided stereoagnosia developed.
Furthermore, pronounced memory impairment and onset of
visuoconstructive and attention deficits were obvious.
Results
Clinical Findings
The clinical data of the CBS patients are summarized in
Table 1. The mean age (68.765 years, range 62–76 years) and the
mean time of follow-up examinations (20.865.2 months, range
14–26 months) were similar to those of the control group (mean
age 60.1610.3 years, range 45–79 years, p = 0.06, Mann-Whit-
ney-U-Test, two-sided; mean follow-up 21.462.7, range 18–
26 months, p = 0.9, Mann-Whitney-U-Test, two-sided).
During the follow-up period CBS patients showed rapid
worsening of clinical symptoms, reflected by a significant increase
of the UPDRS-III score (p = 0.015, t test), the FAST score
(stronger affected limb p=0.36, lesser affected limb p= 0.04, t test)
and the FT scores (stronger affected limb p= 0.04, lesser affected
limb p= 0.004, t test). Asymmetric hypokinetic-rigid syndrome
and ideomotor apraxia were present in all CBS patients. The
second most frequent clinical findings were limb dystonia and
alien limb syndrome in 5/6 patients (83%). Neuropsychological
follow-up assessment revealed pathologic findings particularly in
the domain of initiation and construction. Mild to moderate
memory impairment was present in case 2, 3 and 6.
Neurological and neuropsychological scores of the control
subjects remained in normal range during the course of the entire
study period (Table S1). They revealed constant UPDRS-III (T
initial: 0.961.4; T final: 1.161.3; p = 0.68, Mann-Whitney-U-
Test) and MMSE (T initial: 29.960.3, T final: 29.960.3) values.
Group Comparison of Regional Brain Volume Changes
between CBS Patients and Controls
Table 2 summarizes the between-group comparison of local
volume changes at final follow-up examination (T final) within
anatomically defined regions between CBS patients and healthy
volunteers. Group comparison identified different cortical and
subcortical regions with significant atrophy in CBS patients as
compared to controls. Bilaterally, a highly significant volume loss
of the premotor area 6 and the primary motor area 4 was detected.
Furthermore, the superior parietal lobules of both hemispheres
and the somatosensory area 3a demonstrated a significant volume
decrease relative to controls. Occipital and temporal regions did
not show differences in volume reduction between groups,
although in individual patients we found a reduction of volume.
With respect to the subcortical regions, significant atrophy was
identified in the head of the caudate nucleus, putamen, pallidum
and substantia nigra. In addition, highly significant gray matter
loss was observed within the motor thalamus comprising the
ventral anterior (VA) and ventral lateral (VL) thalamic nuclei.
Furthermore, prominent atrophy of the corticospinal tract and
widening of the ventricles was found. None of the identified
regions revealed significant side-to-side differences.
The complementary voxel-wise analysis of group differences
revealed the same pattern (Figure 1): Cortex and underlying white
matter of the prefrontal and parietal lobes showed strong volume
loss, whereas other parts of the neocortex were spared. Moreover,
head of caudate nucleus, globus pallidus and thalamus were
strongly affected in the patients group.
Comparison of Individual Atrophy Patterns Across CBS
Patients and Healthy Controls
The individual dynamics of brain volume changes in the regions
that revealed significant group differences between CBS patients
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and healthy controls are demonstrated in Figure 2 and Figure 3;
examples of other cytoarchitectonically defined areas are shown in
Figure 4.
Longitudinal DFM analysis in the control group showed only
minimal alterations of the total brain volume. Only ventricles
revealed a mild to moderate increase in total volume after the
follow-up period of 18–26 months. In contrast to these minimal
brain volume changes, individual CBS patients presented severe
and focal atrophy within basal ganglia, thalamus, frontal and
parietal areas. Involved regions thereby revealed different degrees
of spatio-temporal atrophy contralateral as well as ipsilateral to the
clinically most affected side. In all cases, there was a prominent
bilateral, progressive volume loss in the premotor and primary
motor cortex and the corticospinal tract. Patients with shorter
disease durations of 1–2 years at study inclusion (cases 1–4)
showed a more severe volume decline than patients with longer
disease durations of 3–4 years (case 5–6). The contralateral head
of the caudate nucleus, putamen and pallidum were affected in all
CBS patients. The ventral anterior nuclei of the motor thalamus
were most strongly affected and revealed bilateral involvement in
all patients. The rates of volume decline in the substantia nigra
and the posterior parietal cortical regions were not as prominent
and overlapped between CBS patients and normally aging
controls. Atrophy of area 3a was only visible in cases 1, 3, 4 and
6. Interestingly, these patients developed an astereognosia during
clinical follow-up examination. The superior parietal lobule
revealed only mild rates of atrophy. An affection of the temporal
lobe, that did not show significant differences at group compar-
ison, was found in cases 3 and 6 who also presented a cognitive
impairment. The topography of brain volume changes during
longitudinal DFM analysis and the dynamics of progression are
shown in Figure 5.
Discussion
In this study pathological changes in the individual brains of
patients with the clinical diagnosis of CBS were compared to
normal aging in healthy controls using longitudinal DFM analysis
[16]. During two years of follow-up scans, relatively short time
intervals of three to four months revealed the spatio-temporal
dynamics of cortical and subcortical atrophy. In all CBS patients, a
common degeneration within motor circuits, comprising basal
ganglia and motor thalamic nuclei as well as the premotor and
primary motor cortex was present. Clinical long-term follow-up
examination revealed characteristic progressive, asymmetrical
cortical and basal-ganglia features that were unresponsive to
levodopa and supported the diagnosis of CBS [6,21,22].
To increase the in vivo diagnostic accuracy in CBS several
imaging techniques have been proposed to detect neurodegener-
ative brain volume changes [1,6]. One methodological approach
for the differentiation of CBS during lifetime is given by the
visualization of the underlying neurodegeneration using morpho-
metric MRI analysis [3,4,13,33,34]. In this respect, Whitwell and
colleagues only recently showed imaging of atrophy patterns in
autopsy proven subtypes of CBS that were of diagnostic value to
discriminate CBS-CBD, CBS-PSP, CBS-AD and frontotemporal
lobar degeneration with TDP-43 immunoreactivity (CBS-TDP)
[4]. They demonstrated a prominent focal gray matter loss of the
premotor cortex and supplementary cortex in CBS-CBD and
CBS-PSP with sparing of inferior frontal lobe in CBS-PSP. In
CBS-AD and CBS-TDP a more widespread and distinctive
pattern of gray matter loss was shown, with pronounced
frontotemporal volume degeneration suggesting CBS-TDP and
temporoparietal deterioration suggesting CBS-AD. Consistent
with histopathological findings, degeneration of the premotor
and supplementary motor area was evident in all of these different
CBS subtypes reflecting a common pattern of atrophy in these
regions. However, the analysis had a cross-sectional design and did
not identify topography and dynamics of structural changes in
individual patients [4].
Therefore, the novel aspect of our study is the use of DFM
which allows the robust detection and quantification of individual
brain atrophy patterns without predefinition of regions of interest.
We were able to show the course of atrophy progression within
short time intervals of only a few months. Only one report exists,
that used longitudinal voxel-based morphometry analysis in a
single, not autopsy proven patient, who initially presented with a
nonfluent progressive aphasia and later on developed atypical
clinical signs of a CBS [35]. Interestingly, this patient revealed an
akinetic-rigid syndrome, dystonia and alien limb phenomenon
accompanied by an atrophy spreading from the posterior inferior
frontal gyrus to insular regions, thalamus, caudate nucleus and
medial frontal lobe. We also found volume reduction in most of
these areas. Our results demonstrate highest atrophy rates of up to
15% after 26 months in the premotor region, particularily in the
cases with shorter disease duration. This might reflect a
phenomenon of slowing neurodegenerative processes in later
disease stages which has also been shown by neuropathological
and PET studies in Parkinson’s disease [36,37,38]. In addition, we
found in all CBS patients a distinct and asymmetric volume loss in
the substantia nigra, striatum, pallidum, motor thalamic nuclei
including anterior ventral and anterior lateral nuclei as well as the
primary motor cortex. This affection of a functionally intercon-
nected motor circuit concurs with neuropathological results [12]
and also with a deformation tensor imaging study that revealed
structural changes within parts of the same network including the
motor thalamus, the caudate head, the supplementary motor area
and the pre2/postcentral region in CBS patients [2]. Therefore, it
seems very likely that an anatomically specific network undergoes
degeneration in CBS, which causes the clinical symptoms.
In parallel with cortical and subcortical atrophy we detected a
widening of the ventricles. This is in agreement with previously
described ventricular volume increase in CBS that ranges from
8.3% in CBS-AD to 16.2% per annum in CBS-CBD [34], and
with previous aging studies in healthy subjects [39,40].
In contrast to these regionally localized volume changes in CBS
patients, the DFM analysis of the entire brain with follow-up
periods of 18–26 months in healthy controls revealed compara-
tively weak volume alterations, which correspond to reported
changes during normal aging as shown in cross-sectional studies
[41].
All of our patients showed major basal ganglia degeneration
with affection of nigro-striatal regions. It seems plausible that the
akinetic-rigid syndrome, often combined with a limb dystonia, was
caused by this damage. Another prominent clinical finding was an
ideomotor apraxia of at least one limb in all cases as well as an
alien limb phenomenon in 5 out of 6 patients, which previously
has been shown to be associated with affection of the premotor
area [33,42]. A further distinct clinical feature in 4 out of 6
patients (case 1, 3, 4, 6) was the manifestation of a cortical sensory
loss in terms of an astereognosia of the dominantly affected hand.
Interestingly, these patients demonstrated distinct bilateral atrophy
in the somatosensory area 3a. The volume reduction was more
severe on the contralateral side. Tactile object discrimination
depends on the conveyance of multiple afferents from cutaneous
and deep receptors in joints and muscles of an exploring hand.
Hierarchical somatosensory processing of shape is computed by
Brodmann’s areas 3, 1, 2 and parts of the supramarginal gyrus as
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well as the intraparietal sulcus [43,44]. Areas 3a and 3b receive
input from muscle stretch receptors and cutaneous mechanore-
ceptors [44]. Therefore, it is plausible that the present results
explain the cortical sensory loss in CBS. Communication skills
were impaired in 4 patients due to a speech apraxia and dysphasia.
However, none of the subjects developed a primary progressive
aphasia which correlates with our findings of an unaffected Broca’s
area in all of our patients [35]. From human imaging and
lesioning-studies it is known that the superior parietal cortex plays
an important role in visuospatial and attentional processing [45].
Interestingly, the most common neuropsychological impairments
in our patients were visuoconstructive and attention deficits which
might be related to the detected atrophy of the area 5 and 7 of the
parietal lobe. Three patients further developed mild to moderate
memory deficits during clinical follow-up examinations, whereby
the cases 3 and 6 displayed commencing temporal lobe atrophy,
possibly due to an underlying Alzheimer pathology [4,46].
One limitation of our study is the missing post-mortem
confirmed diagnosis making an accurate discrimination of
different nosological entities difficult [6,7,8,9,10]. However, this
is an ongoing follow-up study with the strength that the clinical
features are very accurately documented and the course of the
illness in the examined patients clearly fits the diagnosis of CBS
[6,7,10,11,21,22,47]. Another limitation is that patients were
examined with 1.5 or alternatively 3.0 T MR-scanners. However,
the two different imaging types were matched between groups.
Furthermore, the effect of the different scanners was tested within
the control group and no significant influence on the measurement
of volume changes was found.
In summary, this study shows that longitudinal DFM is a
powerful image analysis tool that supports the investigation of the
course of CBS brain pathology in individual patients during short
time intervals of only a few months, helping to distinguish their
temporal gradient of brain volume changes from that of healthy
aging. DFM may therefore become a sensitive biomarker for a
more accurate clinical diagnosis even at an early disease stage.
Additionally, longitudinal DFM studies could become a helpful
structural imaging method to identify agents that slow, stop, or
even reverse the disease pathology in CBS and also other
neurodegenerative disorders involving the central nervous system.
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